

Amendments to the Claims

This Listing of Claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1.-2. (Cancelled)

3. (Currently Amended) A vaccine composition ~~according to claim 1 wherein~~ comprising a proteosome adjuvant and at least one group A Streptococcal antigen attached to a hydrophobic moiety, wherein the antigen comprises a fragment an antigenic peptide between 6 and 25 amino acids in length of the M-protein from the conserved C-terminal region of an *S. pyogenes* M protein of between 6 and 25 amino acids in length.

4. (Currently Amended) A ~~The~~ vaccine composition according to ~~claim 1~~ claim 3 wherein the ~~antigen—antigenic peptide~~ has the sequence ASREAKKQVEKALE ASREAKKQVEQKALE-(SEQ ID NO:1).

5. (Currently Amended) A ~~The~~ vaccine composition according to claim 2-3 wherein the ~~antigen—antigenic peptide~~ is flanked by amino acid sequences to maintain helical folding of the antigen.

6. (Currently Amended) A ~~The~~ vaccine composition according to claim 5 wherein the ~~peptide—antigen—antigenic peptide~~ has the sequence KQAEKVKASREAKKQVEKALEQLEDKVK-(SEQ ID NO:2).

7. (Currently Amended) A vaccine composition ~~according to claim 1~~ wherein comprising a proteosome adjuvant and a group A streptococcal antigen, wherein the antigen is selected from an MtsA peptide or a protein H peptide.

8. (Currently Amended) ~~A-The vaccine composition according to claim 1-3 wherein the antigenic peptide further comprises a C- or N-terminal hydrophobic moiety is attached at the N-terminal end or C-terminal end of the antigen for insertion of the antigenic peptide into proteosome adjuvant vesicles complexing the antigen with the proteosome adjuvant.~~

9. (Currently Amended) ~~A-The vaccine composition according to either claim 1-3 or claim 7 for parenteral or oral administration wherein the composition is formulated for mucosal administration.~~

10. (Currently Amended) ~~A-The vaccine composition according to claim 9 for wherein mucosal administration is intranasal administration.~~

11. - 12. (Cancelled)

13. (Currently Amended) ~~A-The vaccine composition according to claim 1-3 wherein administration of the composition to the an individual induces a mucosal immune response.~~

14. (Currently Amended) ~~A-The vaccine composition according to claim 1-3, wherein administration of the vaccine composition induces a serum immune response.~~

15. (Currently Amended) ~~A-The vaccine composition according to claim 1-9 wherein the vaccine composition is capable of treating or preventing a administered intranasally to the individual and treatment or prophylaxis of group A Streptococcal infection via is produced via reduction or prevention of reducing or preventing streptococcal group A bacterial colonisation of the throat.~~

16. (Currently Amended) A method of treatment ~~of~~or prophylaxis of group A Streptococcal infection in an individual comprising administering ~~a~~the vaccine composition according to either claim 1-3 or claim 7 to the individual.

17. (Currently Amended) ~~A~~The method according to claim 16 wherein said vaccine composition is administered intranasally to said individual.

18. (Currently Amended) ~~A~~The method according to claim 17 wherein the treatment or prophylaxis of the group A Streptococcal infection is produced via prevention or reduction of bacterial colonisation of the throat.

19. (New) The vaccine composition according to claim 3 wherein the antigen further comprises a spacer peptide comprising at least two glycine residues, and wherein the spacer peptide links the antigenic peptide and the hydrophobic moiety.